A framework for in silico prediction of drug safety and efficacy in populations of human cardiac cell models

Applications: Drug discovery, drug development

Virtual Assay V4 brings electrophysiology and contractility together in a single, validated, human-based mechanistic framework — enabling early, quantitative prediction of both electrical and mechanical cardiac risk.

Features	Benefits
Simultaneous prediction of proarrhythmic and inotropic risk	More informed portfolio decisions
Quantitatively validated contractility prediction (86–95% agreement benchmarks)	Smarter experimentation
Human-specific modelling eliminating species translation issues	Reduced reliance on ex vivo animal testing through human-based modelling
Mechanistic, auditable drug–channel–tension traceability	Earlier de-risking
Population-level risk stratification

Available for:

Licensing
Co-development
Consulting

Request more information
about this technology

Back to Technologies Available

Technologies for License

A framework for in silico prediction of drug safety and efficacy in populations of human cardiac cell models

Ready to get in touch?